Biotech · Public company · San Diego, CA, US
BlossomHill Therapeutics, Inc.
Ticker BLSM · SEC CIK 0001839970
Track this companyFree. Adds BlossomHill Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials22 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline4
- BH-30643Phase 2 · NSCLC (Advanced Non-small Cell Lung Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
- BH-30643 combo therapy with Carboplatin/PemetrexedPhase 2 · NSCLC (Advanced Non-small Cell Lung Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
- BH-30236Phase 1 · LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 1 · LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 MutationsPHASE1_PHASE2 · RECRUITING · started Jan 9, 2025ClinicalTrials.gov NCT06706076 · fetched Nov 12, 2026
- A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic SyndromePHASE1 · RECRUITING · started Jun 19, 2024ClinicalTrials.gov NCT06501196 · fetched Nov 12, 2026
SEC filings7
- 10-Q · 10-QSEC EDGAR · filed Sep 18, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 18, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 15, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 424B4 · 424B4SEC EDGAR · filed Aug 7, 2026 · fetched Nov 12, 2026
- S-1/A · S-1/A: AMENDMENT NO. 1SEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- S-1 · S-1SEC EDGAR · filed Jul 17, 2026 · fetched Nov 12, 2026